Oesophagitis, reflux

Y. Vandenplas, H. Badriul, M. Verghote, B. Hauser, and L. Kaufman, Oesophageal pH monitoring and reflux oesophagitis in irritable infants. EurJ. Pediatr. 163, 300-304 (2004). 

Kawamura, M., Ohara, S., Koike, T., et al. (2003) The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment. Pharmacol. Ther. 

Omeprazole is more effective than H2 blockers in producing achlorhydria when repeated doses are used in treating peptic ulceration or reflux oesophagitis. However, it is less effective than these in reducing volume and acidity of stomach contents when given as a single preoperative dose, and has no advantage over H2 blockade in this situation. 

Sucralfate is used in the management of peptic ulceration and of reflux oesophagitis, and its cytoprotective effects may be of benefit in radiation-induced mucosal damage elsewhere in the GI tract. 

Use H7K+-ATPase-inhibitory ulcer therapeutic (Zollinger-Ellison Syndrom, reflux oesophagitis)... 

Laker MK, Cookson JC. Reflux oesophagitis and clozapine. Int Clin Psychopharmacol 1997 12(l) 37-9. 

Alginic acid may be combined with an antacid to encourage adherence of the mixture to the mucosa, e.g. for reflux oesophagitis. 

Oesophagogastroscopy An ascites-related gastro-oeso-phageal reflux can result in reflux oesophagitis. However, this does not provoke the onset of bleeding from oesophageal varices. 

KahrUas PJ, Falk GW, Johnson DA, Schmitt C, ColUns DW, Whipple J, D Amico D, Hamelin B, Joelsson B. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000 14(10) 1249-58. 

Mulder CJ, Westerveld BD, Smit JM, Oudkerk Pool M, Otten MH, Tan TG, van MUligen de Wit AW, de Groot GH, Dutch omeprazole MUPS study group. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment a Dutch multicentre trial. Eur J Gastroenterol Hepatol 2002 14(6) 649-56. 

Bardhan KD, Van Rensburg C. Comparable cUnical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis. Aliment Pharmacol Ther 2001 15(10) 1585-91. 

FUT-187) is a naphthalenyllmidazolylaminobenzoate, an ENZYME INHIBITOR active as a (serine) PROTEASE INHIBITOR. It can be used as a proteolysis inhibitor in the treatment of postgastrectoiTty reflux oesophagitis, sepimostat methanesulfonate sepimostat. septide ([pGlu Pro ] Pe.n) is a substance P derivative, a TACHYKININ RECEPTOR AGONIST, selective at the NK -receptor subtype. It is used as a pharmacological tool. 

Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grad II, III and IV (a Dutch multicentre trial). Dutch Study Group. Eur J Gastroenterol Hepatol 1996 8 1101-1106. 

Mossner J, Holscher AH, Herz R, et al. A double-blind study of pantopra-zole and omeprazole in the treatment of reflux oesophagitis A multi centre trial. Aliment Pharmacol Ther 1995 9 321-326. 

Gough AL, Long RG, Cooper BT. Lansoprazole versus ranitidine in the maintenance of reflux oesophagitis. Aliment Pharmacol Ther 1996 10 529-539. 

Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole vs ranitidine for prevention of relapse in reflux oesophagitis A controlled double blind trial of their efficacy and safety. Gut 1994 35 590-598. 

Boekent MV and Beker JA (1988) Treatment of ulcerative reflux oesophagitis with colloidal bismuth subcitrate in combination with cimetidine. Gut 29 385-389. 

A 73-year-old man taking levodopa/benserazide and bromocriptine for Parkinson s disease was given lansoprazole 15 mg daily to treat reflux oesophagitis. Two days later, the patient exhibited akinesia (more motor difficulties and slowness in movements) associated with frequent falls. Lansoprazole was discontinued, with disappearance of the symptoms the day after. About 3 months later the patient was prescribed omeprazole 20 mg daily, which caused no aggravation of Parkinson s disease over the following 6 months. 

---